The Current and Emerging Role of Immune Checkpoint Inhibitors in the Management of Lung Cancer

A CME Symposium During the 16th World Conference on Lung Cancer

TARGET AUDIENCE
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of non-small cell lung cancer (NSCLC).

OVERVIEW OF ACTIVITY
Lung cancer is a broad-reaching and devastating disease representing approximately 13% of all new cancer cases and 27% of all cancer deaths annually in the United States. However, the past several years have seen an explosion in the emergence of new potential therapies that leverage the natural ability of the human body to attack and treat cancer. Known as immune-mediated therapies or cancer immunotherapies, these promising treatments are taking center stage at medical conferences and generating excitement all over the world.

These video proceedings from a CME symposium held in conjunction with the 16th World Conference on Lung Cancer feature discussions with leading researchers with an expertise in the management of lung cancer regarding actual patient cases and related clinical research findings relevant to immunotherapy to address existing uncertainties and help keep clinicians up to date and informed on the current and future role of immunotherapies in the management of lung cancer.

LEARNING OBJECTIVES
• Analyze the biologic basis for various immunotherapeutic strategies designed to boost an individual’s immune response to combat cancer.
• Compare and contrast the mechanisms of action, efficacy and safety/toxicity of immunotherapies under investigation for the treatment of lung cancer.
• Appraise the rationale for and clinical data with investigational anti-PD-1 and anti-PD-L1 antibodies for patients with lung cancer.
• Recognize immune-related adverse events and other common side effects associated with approved and developmental immunotherapeutic agents in order to offer supportive management strategies.
• Recall the design of ongoing clinical trials evaluating novel immunotherapeutic approaches, and counsel appropriately selected patients with lung cancer about availability and participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 75% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/IASCLCImmunotherapy15/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:
Scott N Gettinger, MD
Associate Professor of Medicine, Medical Oncology
Yale School of Medicine
Thoracic Oncology Program
Developmental Therapeutics
Smilow Cancer Hospital at Yale-New Haven
New Haven, Connecticut

ResearchToPractice.com/IASCLCImmunotherapy15
No real or apparent conflicts of interest to disclose.

**Jean-Charles Soria, MD, PhD**
Full Professor, Paris University XI
Head of Drug Development Department
Institut Gustave Roussy
Villejuif, France

**Advisory Committee:** AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Genentech BioOncology, GlaxoSmithKline, Merck, Roche Laboratories Inc, Sanofi; **Consulting Agreements:** AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, GlaxoSmithKline, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly, Merck, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Sanofi.

**David R Spigel, MD**
Program Director
Lung Cancer Research
Sarah Cannon Research Institute
Nashville, Tennessee

**Advisory Committee:** Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Lilly, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc; **Consulting Agreement:** AstraZeneca Pharmaceuticals LP.

**MODERATOR — Dr Love** is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacists Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

**RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS** — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company and Genentech BioOncology.

**Hardware/Software Requirements:**
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

**Last review date:** November 2015

**Expiration date:** November 2016
Scott N Gettinger, MD
An open-label randomized phase III trial of BMS-936558 (nivolumab) versus docetaxel in previously treated advanced or metastatic squamous cell non-small cell lung cancer (NSCLC). NCT01642004

An open-label randomized phase III trial of BMS-936558 (nivolumab) versus docetaxel in previously treated metastatic non-squamous non-small cell lung cancer (NSCLC). NCT01673867

MDX1106-03: A phase 1b, open-label, multicenter, multidose, dose-escalation study of MDX-1106 in subjects with selected advanced or recurrent malignancies. NCT00730639


Spigel DR et al. A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC). Proc ASCO 2015;Abstract 8009.


David R Spigel, MD
Spigel DR et al. A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC). Proc ASCO 2015;Abstract 8009.

Spira AI et al. Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR). Proc ASCO 2015;Abstract 8010.


Wolchok JD et al. Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). Proc ASCO 2015;Abstract LBA1.

Jean-Charles Soria, MD, PhD
A phase 1b study of the safety and pharmacology of MPDL3280A administered with erlotinib or alectinib in patients with advanced non-small cell lung cancer. NCT02013219

A phase I, open-label, multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of gefitinib in combination with MEDI4736 (anti PD-L1) in subjects with non-small cell lung cancer. NCT02088112

A phase Ib study of the safety and pharmacology of MPDL3280A administered with bevacizumab and/or with chemotherapy in patients with advanced solid tumors. NCT01633970

A phase III prospective double blind placebo controlled randomized study of adjuvant MEDI4736 in completely resected non-small cell lung cancer. NCT02273375


CheckMate 012: A multi-arm phase I safety study of nivolumab in combination with gemcitabine/cisplatin, pemetrexed/cisplatin, carboplatin/paclitaxel, bevacizumab maintenance, erlotinib, ipilimumab or as monotherapy in subjects with stage IIIB/IV non-small cell lung cancer (NSCLC). NCT01454102

GEFTREM: Phase I, open-label, safety, tolerability and preliminary efficacy study of tremelimumab in combination with gefitinib in EGFR mutant NSCLC patients. NCT01454102

IMpower 110: A phase III, open-label, randomized study of MPDL3280A (anti-PDL1 antibody) compared with cisplatin or carboplatin + pemetrexed for PD-L1-selected chemotherapy naive patients with IV non-squamous non-small cell lung cancer. NCT02409342
IMpower 130: A phase III multicenter, randomized, open-label study evaluating the efficacy and safety of MPDL3280A (anti-PD-L1 antibody) in combination with carboplatin + nab-paclitaxel for chemotherapy-naive patients with stage IV non-squamous non-small cell lung cancer. NCT02367781

IMpower 150: A phase III, open-label, randomized study of MPDL3280A (anti-PD-L1 antibody) in combination with carboplatin + paclitaxel with or without bevacizumab compared with carboplatin + paclitaxel + bevacizumab in chemotherapy-naïve patients with stage IV non-squamous non-small cell lung cancer (NSCLC). NCT02366143

Ipilimumab plus targeted inhibitor (erlotinib or crizotinib) for EGFR or ALK mutated stage IV non-small cell lung cancer: Phase Ib with expansion cohorts. NCT01998126


MK-3475-021/KEYNOTE-021: A phase I/II study of MK-3475 (SCH900475) in combination with chemotherapy or immunotherapy in patients with locally advanced or metastatic non-small cell lung carcinoma. NCT02039674

MYSTIC: A phase III randomized, open-label, multi-center, global study of MEDI4736 in combination with tremelimumab therapy or MEDI4736 monotherapy versus standard of care platinum-based chemotherapy in first line treatment of patients with advanced or metastatic non small-cell lung cancer (NSCLC). NCT02453282


Pilot study of MPDL3280A plus stereotactic ablative radiotherapy (SAR) in stage IV non-small cell lung cancer. NCT02400814